Work on the final validation of the facility to ensure compliance with EU Good Manufacturing Practices (GMP) is underway and once fully licensed the increased capacity will allow the company to significantly expand the number and range of vaccines it produces.
The 2,500-square-metre facility is set to be one of the most capable EU GMP antigen production facilities in Europe.
"This is a significant milestone for Benchmark,” commented Malcolm Pye, Benchmark CEO. “The new facility provides the foundation for the large-scale antigen manufacture and testing of our new pipeline products, and represents the engine room through which our ground-breaking products can be delivered on a large commercial scale."
Bagikan Berita Ini
Related Posts :
High hopes for new sea lice system
The new treatment, Ectosan, which has been developed by Benchmark, was delivered through the c… Read More...- Russian salmon firm raises £12 millionRussia’s largest aquaculture company - which produces salmon and trout in Russia, as well as sm… Read More...
- Algal feed firm eyes up US oyster opportunities
The US produces 1.4 million tonnes of oysters a year, making it the world’s largest producer of the… Read More...
- BioMar plans 110,000 tonne Tasmanian aquafeed factory
Paddy Campbell, Managing Director of BioMar UK, Australia and the Northern Sea Region, said the mil… Read More...
- Boost for carp and tilapia breeders
In a recent article, Dr John Benzie, who leads the organisation’s genetics work, explained how Worl… Read More...
0 Response to "First batch produced by new fish vaccine facility"
Post a Comment